Cited 11 times in
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 남정모 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 안중배 | - |
dc.contributor.author | 양우익 | - |
dc.contributor.author | 임승택 | - |
dc.contributor.author | 전홍재 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 정희철 | - |
dc.contributor.author | 홍민희 | - |
dc.contributor.author | 강버들 | - |
dc.contributor.author | 박지수 | - |
dc.date.accessioned | 2015-01-06T17:21:02Z | - |
dc.date.available | 2015-01-06T17:21:02Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/99814 | - |
dc.description.abstract | PURPOSE: We conducted a phase II study evaluating safety and efficacy of combination gemcitabine and capecitabine therapy for metastatic breast cancer patients following anthracycline and taxane treatment in Korea. METHODS: This was a single-arm, non-randomized phase II study. Patients received 1,000 mg/m(2) gemcitabine intravenously over 30 min on days 1 and 8, and 1,250 mg/m(2) capecitabine orally twice daily on days 1-14 until disease progression or intolerable toxicity occurred. This regimen was repeated every 3 weeks. The primary outcome assessed was overall response rate [ORR, complete response (CR) + partial response (PR) as the best response], and secondary outcomes were progression-free survival (PFS), overall survival (OS), disease control rate (DCR) [maintenance of CR + PR + stable disease (SD) for at least 3 months], drug toxicity, and predictive factors for response to this regimen. RESULTS: Of 41 patients, the ORR was 39.0% (CR 0%; PR 39.0%), and DCR was 78.0% using this chemotherapy. DCR for 6 and 12 months was 68.3 and 26.8%, respectively. Median PFS was 10.0 months [95% confidence interval (CI) 7.8-12.1], and median OS was 25.1 months (95% CI 18.2-32.1). Prominent toxicities were neutropenia and hand-foot syndrome. Most adverse events were well known, relatively moderate, and reversible. Taxane sensitivity [odds ratio (OR) 0.169; 95% CI 0.034-0.826; P = 0.028] and hepatic metastasis (OR 0.097; 95% CI 0.017-0.559; P = 0.009) were significantly predictive of response to gemcitabine and capecitabine combination. CONCLUSIONS: This study showed reproducible anticancer activity and tolerable toxicity of gemcitabine and capecitabine combination therapy in recurrent or metastatic Korean breast cancer patients previously treated with anthracycline and taxane. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Anthracyclines*/administration & dosage | - |
dc.subject.MESH | Anthracyclines*/adverse effects | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols | - |
dc.subject.MESH | Breast Neoplasms*/drug therapy | - |
dc.subject.MESH | Breast Neoplasms*/mortality | - |
dc.subject.MESH | Breast Neoplasms*/pathology | - |
dc.subject.MESH | Bridged-Ring Compounds*/administration & dosage | - |
dc.subject.MESH | Bridged-Ring Compounds*/adverse effects | - |
dc.subject.MESH | Capecitabine | - |
dc.subject.MESH | Deoxycytidine/administration & dosage | - |
dc.subject.MESH | Deoxycytidine/adverse effects | - |
dc.subject.MESH | Deoxycytidine/analogs & derivatives* | - |
dc.subject.MESH | Disease Progression | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Drug Screening Assays, Antitumor | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Fluorouracil/adverse effects | - |
dc.subject.MESH | Fluorouracil/analogs & derivatives* | - |
dc.subject.MESH | Hand-Foot Syndrome*/etiology | - |
dc.subject.MESH | Hand-Foot Syndrome*/physiopathology | - |
dc.subject.MESH | Hand-Foot Syndrome*/prevention & control | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Recurrence, Local* | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Neutropenia*/chemically induced | - |
dc.subject.MESH | Neutropenia*/physiopathology | - |
dc.subject.MESH | Neutropenia*/prevention & control | - |
dc.subject.MESH | Republic of Korea/epidemiology | - |
dc.subject.MESH | Severity of Illness Index | - |
dc.subject.MESH | Taxoids*/administration & dosage | - |
dc.subject.MESH | Taxoids*/adverse effects | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pathology (병리학) | - |
dc.contributor.googleauthor | Ji Soo Park | - |
dc.contributor.googleauthor | Hei-Cheul Jeung | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Joong Bae Ahn | - |
dc.contributor.googleauthor | Beodeul Kang | - |
dc.contributor.googleauthor | Hong Jae Chon | - |
dc.contributor.googleauthor | Min Hee Hong | - |
dc.contributor.googleauthor | Seungtaek Lim | - |
dc.contributor.googleauthor | Woo Ick Yang | - |
dc.contributor.googleauthor | Chung Mo Nam | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.identifier.doi | 10.1007/s00280-014-2551-4 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01264 | - |
dc.contributor.localId | A02262 | - |
dc.contributor.localId | A02300 | - |
dc.contributor.localId | A03380 | - |
dc.contributor.localId | A03565 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A04393 | - |
dc.contributor.localId | A00029 | - |
dc.contributor.localId | A03794 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.pmid | 25107569 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00280-014-2551-4 | - |
dc.subject.keyword | Breast cancer | - |
dc.subject.keyword | Metastatic | - |
dc.subject.keyword | Recurrent | - |
dc.subject.keyword | Gemcitabine | - |
dc.subject.keyword | Capecitabine | - |
dc.subject.keyword | Chemotherapy | - |
dc.contributor.alternativeName | Nam, Jung Mo | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | Ahn, Joong Bae | - |
dc.contributor.alternativeName | Yang, Woo Ick | - |
dc.contributor.alternativeName | Lim, Seung Taek | - |
dc.contributor.alternativeName | Chon, Hong Jae | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.alternativeName | Jeung, Hei Cheul | - |
dc.contributor.alternativeName | Hong, Min Hee | - |
dc.contributor.alternativeName | Kang, Beo Deul | - |
dc.contributor.affiliatedAuthor | Nam, Jung Mo | - |
dc.contributor.affiliatedAuthor | Ahn, Joong Bae | - |
dc.contributor.affiliatedAuthor | Yang, Woo Ick | - |
dc.contributor.affiliatedAuthor | Lim, Seung Taek | - |
dc.contributor.affiliatedAuthor | Chon, Hong Jae | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Hong, Min Hee | - |
dc.contributor.affiliatedAuthor | Kang, Beo Deul | - |
dc.contributor.affiliatedAuthor | Jeung, Hei Cheul | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 74 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 799 | - |
dc.citation.endPage | 808 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.74(4) : 799-808, 2014 | - |
dc.identifier.rimsid | 49619 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.